Last updated 2026-07-27
- Went public on NASDAQ, Dec 2006
- Raised $35M Follow-on PO, Oct 2020
- Raised $43.7M PIPE, Mar 2020
Total raised
$244.4M
Last: Public Offering 2021-02
Stage
Public
Founded
1993
Headcount
226
HQ
Karmiel, Israel
Sector
Health Tech & Life Sciences
About
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures plant-based enzymes. It focuses on the discovery, development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based protein expression system. The company has two FDA-approved products: Elelyso (taliglucerase alfa) for Gaucher disease and Elfabrio (pegunigalsidase alfa) for Fabry disease. Protalix collaborates with Pfizer Inc. and Chiesi Global Rare Diseases.
Funding history · 16 rounds · $244.4M total
2025-08
Follow-on PO
$15.7M
2025-03
Follow-on PO
$20.0M
2022-05
Follow-on PO
$20.0M
2021-07
Follow-on PO
$20.0M
2021-07
Follow-on PO
$13.8M
2020-10
Follow-on PO
$35.0M
2020-03
PIPE
$43.7M
2015-09
PIPE
$10.0M
★ Pfizer
2012-01
Follow-on PO
$25.4M
★ Jefferies & Company, Inc.Canaccord Genuity Inc.Oppenheimer & Co. Inc.
2011-02
Follow-on PO
$22.0M
★ Biocell Ltd.★ US institutional investors
2010-10
Follow-on PO
Undisclosed
2009-02
Grant
$6.0M
2008-03
Grant
$4.0M
2006-11
Follow-on PO
Undisclosed
2005-07
C Round
$5.3M
★ Phillip Frost★ Aliment Capital★ Docor International Management
2004-09
B Round
$3.5M
Headcount over time
From 158 (2018-09) to 195 (2025-12) · +37 (+23%) · 57 points · source: Finder history + radar grounding
Q&A
- What is Protalix BioTherapeutics' primary focus?
- Protalix BioTherapeutics is a biopharmaceutical company that develops plant cell-expressed enzyme replacement therapies for rare lysosomal storage disorders.
- When did Protalix BioTherapeutics go public on the NYSE?
- Protalix BioTherapeutics went public on the NYSE in March 2011.
- What is the employee count for Protalix BioTherapeutics?
- Protalix BioTherapeutics has 226 employees, falling within the 201-500 employee bucket.
- What was the amount raised in Protalix BioTherapeutics' Public Offering in February 2023?
- In February 2023, Protalix BioTherapeutics raised $20,000,000 in a Public Offering.
- What was the amount raised in Protalix BioTherapeutics' most recent Public Offering in March 2025?
- In March 2025, Protalix BioTherapeutics raised $20,000,000 in a Public Offering.
- What are the two FDA-approved products developed by Protalix BioTherapeutics?
- Protalix BioTherapeutics has two FDA-approved products: Elelyso (taliglucerase alfa) for Gaucher disease and Elfabrio (pegunigalsidase alfa) for Fabry disease.
- Which companies does Protalix BioTherapeutics collaborate with?
- Protalix BioTherapeutics collaborates with Pfizer Inc. and Chiesi Global Rare Diseases.
- When did Protalix BioTherapeutics announce the appointment of Gilad Mamlok as its new Senior Vice President and Chief Financial Officer?
- Protalix BioTherapeutics announced the appointment of Gilad Mamlok as its new Senior Vice President and Chief Financial Officer on July 21, 2025.
- When did Protalix BioTherapeutics and Secarna Pharmaceuticals enter into a collaboration and option agreement?
- Protalix BioTherapeutics and Secarna Pharmaceuticals entered into a collaboration and option agreement on December 17, 2025.
- When did Chiesi Global Rare Diseases and Protalix BioTherapeutics receive a positive CHMP opinion for an additional dosing regimen of Elfabrio in the EU?
- Chiesi Global Rare Diseases and Protalix BioTherapeutics received a positive CHMP opinion for an additional dosing regimen of every four weeks for Elfabrio (pegunigalsidase alfa) in the EU on January 30, 2026.
Team · 1
Yoseph Shaaltiel
Founder · Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
antibodiesoral-drugspharmaceuticalsproteinsgenetic-disordersplant-proteininflammatory-diseasespharma-companiesdrug-development
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | protalix.com |
|---|---|
| linkedin.com/company/739969 | |
| X / Twitter | twitter.com/protalix_bio |
| facebook.com/ProtalixBio | |
| Wikipedia | en.wikipedia.org/wiki/Protalix_BioTherapeutics |
| Wikidata | wikidata.org/wiki/Q7251166 |
Identifiers & details
| Legal name | Protalix BioTherapeutics Inc. |
|---|---|
| Founded | 1993 |
| Employees (exact) | 226 |
| Market cap | $79.2M |
| Status reason | Public on AMEX on Dec, 2006;Public on TASE on Nov, 2010;Public on NYSE on Mar, 2011; |
| Wikidata QID | Q7251166 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| Reverse Merger | 2006-12 | NASDAQ | ||
| Public Offering | 2010-11 | TASE | PLX | |
| Public Offering | 2011-03 | NYSE | PLX | $22.0M |
| Public Offering | 2012-02 | NYSE American | PLX | $25.4M |
| Public Offering | 2021-02 | NYSE American | PLX | $40.0M |
Radar intelligence
Web history (Wayback)
| Domain | protalix.com |
|---|
Wikidata
| QID | Q7251166 |
|---|
Certificate / subdomain footprint
| Subdomains | 8 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 511903288 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 1993-12-27 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 1 |
| Registry events | 3 — people (2), charge (1) |
| Registered address | סנונית 2 כרמיאל |
Recent registry events
| Date | Event |
|---|---|
| 2025-11-24 | עדכון דירקטורים-הוספת דירקטור |
| 2025-11-24 | עדכון דירקטורים-הסרת דירקטור |
| 2025-12-17 | רישום שעבוד |